HOME >> BIOLOGY >> NEWS
Tweaking Taxol points way to a greener, more productive future

As the effective cancer-treatment drug Taxol enters its next generation, Michigan State University announces discoveries which point to both environmentally friendly ways to produce more Taxol, and ultimately innovations to produce a more potent second-generation drug.

Kevin Walker, a chemistry and biochemistry and molecular biology assistant professor, in the March 24 issue of Chemistry & Biology, reports a step toward manufacturing more-potent Taxol molecules that could potentially reduce treatment dosages. The methods described minimize dangerous chemical usage, and put E.coli to work in the production process.

"We're trying to develop a biosynthetic process for the drugs that circumvents the use of organic solvent-based methods requiring costly waste management," Walker said. "This attempt is a green chemistry approach to produce more potent versions of Taxol."

Taxol generically known as paclitaxel is a top-selling cancer-fighting drug. It's most commonly used against ovarian and breast cancers, but currently is used in certain aspects of heart disease treatment, and is showing promise in Alzheimer's therapy.

Taxol is derived in small quantities from the Pacific yew tree. To fulfill large-scale production, pharmaceutical companies isolate, from the tree, an abundant natural product that is synthetically converted to Taxol in the laboratory.

Now, as abundant molecules from the yew are being synthetically modified for new, more potent versions of Taxol, Walker, along with Catherine Loncaric, a visiting research associate, and undergraduate Erin Merriweather, is looking for alternative, biological routes to introduce the modifications. Walker's laboratory makes use of recently identified genes of the yew that produce enzymes that craft the pathway to Taxol. The targets: five enzymes that biosynthetically decorate the core of the Taxol molecule.

The enzymes in natural and, potentially, genetically modified form can
'"/>


24-Mar-2006


Page: 1 2

Related biology news :

1. Tweaking the treatment for restless legs
2. Protein identified that regulates effectiveness of Taxol chemotherapy in breast cancer
3. Tipping points
4. Study points to new way to predict death risk from torn aorta
5. Genes activity points to more lethal subtype of AML
6. Existence of muscle-building stem cells points to regenerative therapies for muscular disease
7. Newly identified mechanism for silencing genes points to possible anti-cancer strategies
8. Massive gene screening points way to more effective chemotherapy
9. Lizards shout against a noisy background to get points across
10. International study points to new breast cancer-susceptibility gene
11. Imaging pinpoints brain regions that see the future

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, ... that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational ... the treatment of severe COVID-19. Approval of this IND allows Sentien to initiate ...
(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, based ... entered into license agreements with Housey Pharma’s HMI subsidiary to gain access to ... have annual Research and Development spending in excess of US $10 billion. , ...
(Date:8/5/2020)... ... August 05, 2020 , ... Regenative Labs has received approval from ... and ProText™, making them the first Wharton’s jelly allografts to be assigned a Q ... company’s solutions are the first Wharton’s jelly allograft product to be recognized as a ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and positions ... as MediVet Biologics since its formation in 2016, the company is relaunching itself under ... build on its base of innovative therapies for osteoarthritis and cancer. , ...
(Date:7/31/2020)... CAMBRIDGE, Mass. and SOMERSET, N.J (PRWEB) , ... ... ... a leading genome editing company, and Catalent, the leading global provider of advanced ... and consumer health products, today announced that they have entered into a strategic ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... After research ... The completion of a great surgery is only the beginning of a successful study, ... research community. , Join Brad Gien, Global Head of Surgery from Envigo ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Massachusetts Institute of Technology (MIT) has expanded the company’s exclusive license to ... move into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. ...
Breaking Biology Technology:
Cached News: